2023 ESMO Congress Research Highlights

Prostate Cancer Updates - GU Oncology Conference Highlights: ESMO 2023 Video

Prostate Cancer Updates - GU Oncology Conference Highlights: ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2023.
Kidney Cancer Updates - GU Oncology Conference Highlights: ESMO 2023 Video

Kidney Cancer Updates - GU Oncology Conference Highlights: ESMO 2023

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2023.
Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023 News

Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology (ESMO) Congress 2023 in Madrid, Spain.
Dual-Action Drug Produces Positive Results in Patients with Advanced Neuroendocrine Tumors, Trial Finds News

Dual-Action Drug Produces Positive Results in Patients with Advanced Neuroendocrine Tumors, Trial Finds

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber.
Kidney Cancer Study Shows Improved Outcomes for Patients with Advanced Disease when Treated with Belzutifan over Everolimus News

Kidney Cancer Study Shows Improved Outcomes for Patients with Advanced Disease when Treated with Belzutifan over Everolimus

Patients previously treated with immune checkpoint inhibitors and anti-angiogenics showed improved progression free survival with no new safety concerns.